BioSpace News Archive

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three and nine months ended September 30, 2019 and provided a corporate update.

Mapi Pharma Ltd. announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple sclerosis (RMS).

New analyses from Phase 3 REGENERATE study evaluating the effects of OCA on non-invasive liver fibrosis tests and NASH patient-reported outcomes

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates.

Initial Purchase of $1 Million of Salarius Shares Completed, Aspire Capital to Purchase Additional Salarius Common Stock over a 30-Month Span Extending into 2022

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the results of a Phase 2 study of NYX-2925 in patients with fibromyalgia have been selected for a late-breaking poster presentation at the American College of Rheumatology Annual Meeting

Astellas Pharma US, Inc. (“Astellas”) today announced it has awarded $200,000 in total grants and resources to winners of the fourth annual C3 (Changing Cancer Care) Prize, a challenge that funds the best ideas beyond medicine to improve cancer care for patients, caregivers and their loved ones.

Theragun, Inc., the leader in hand-held percussive therapy devices, has entered into a comprehensive partnership with Life Time, the nation’s premier healthy lifestyle brand.

Nuvation Bio, Inc., a stealth biotechnology company developing proprietary therapies focused on oncology, announces the closing of $275 million in an oversubscribed Series A financing.

Inflammatory Breast Cancer (IBC) Research Foundation, Susan G. Komen®, and the Milburn Foundation® have again come together to become a powerful force against inflammatory breast cancer (IBC) – an aggressive subtype of breast cancer that is challenging to diagnose and treat